Schizotypal Traits are Linked to Dopamine-Induced Striato-Cortical Decoupling: A Randomized Double-Blind Placebo-Controlled Study.


Journal

Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760

Informations de publication

Date de publication:
25 04 2019
Historique:
pubmed: 8 6 2018
medline: 21 4 2020
entrez: 8 6 2018
Statut: ppublish

Résumé

The dopamine hypothesis of schizophrenia implies that alterations in the dopamine system cause functional abnormalities in the brain that may converge to aberrant salience attribution and eventually lead to psychosis. Indeed, widespread brain disconnectivity across the psychotic spectrum has been revealed by resting-state functional magnetic resonance imaging (rs-fMRI). However, the dopaminergic involvement in intrinsic functional connectivity (iFC) and its putative relationship to the development of psychotic spectrum disorders remains partly unclear-in particular at the low-end of the psychosis continuum. Therefore, we investigated dopamine-induced changes in striatal iFC and their modulation by psychometrically assessed schizotypy. Our randomized, double-blind placebo-controlled study design included 54 healthy, right-handed male participants. Each participant was assessed with the Schizotypal Personality Questionnaire (SPQ) and underwent 10 minutes of rs-fMRI scanning. Participants then received either a placebo or 200 mg of L-DOPA, a dopamine precursor. We analyzed iFC of 6 striatal seeds that are known to evoke modulation of dopamine-related networks. The main effect of L-DOPA was a significant functional decoupling from the right ventral caudate to both occipital fusiform gyri. This dopamine-induced decoupling emerged primarily in participants with low SPQ scores, while participants with high positive SPQ scores showed decoupling indifferently of the L-DOPA challenge. Taken together, these findings demonstrate that schizotypal traits may be the result of dopamine-induced striato-occipital decoupling.

Identifiants

pubmed: 29878280
pii: 5033920
doi: 10.1093/schbul/sby079
pmc: PMC6483584
doi:

Substances chimiques

Dopamine Agents 0
Levodopa 46627O600J
Dopamine VTD58H1Z2X

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

680-688

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

Curr Neurol Neurosci Rep. 2016 Oct;16(10):91
pubmed: 27568202
JAMA Psychiatry. 2016 Aug 1;73(8):862-70
pubmed: 27145361
Neuropsychopharmacology. 2011 Sep;36(10):2009-17
pubmed: 21654735
Neuroimage. 2007 Aug 1;37(1):90-101
pubmed: 17560126
Front Psychol. 2017 Sep 07;8:1537
pubmed: 28936192
Br J Psychiatry. 1987 Dec;151:735-43
pubmed: 3332195
J Neurosci. 2008 Apr 2;28(14):3697-706
pubmed: 18385328
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1279-84
pubmed: 19164577
Prog Neurobiol. 2017 Jan;148:1-20
pubmed: 27890810
Eur J Pharm Biopharm. 2003 Jan;55(1):71-6
pubmed: 12551706
Brain Res Bull. 2009 Feb 16;78(2-3):69-74
pubmed: 18950692
Front Hum Neurosci. 2013 Dec 27;7:885
pubmed: 24409134
Schizophr Bull. 1994;20(1):191-201
pubmed: 8197415
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Psychol Med. 2013 Jun;43(6):1133-49
pubmed: 22850401
Curr Opin Neurobiol. 1997 Apr;7(2):157-63
pubmed: 9142758
Schizophr Bull. 2000;26(3):603-18
pubmed: 10993401
Schizophr Bull. 2015 Mar;41 Suppl 2:S417-26
pubmed: 25810056
Trends Cogn Sci. 2000 Jun;4(6):223-233
pubmed: 10827445
Trends Neurosci. 2014 Feb;37(2):85-94
pubmed: 24388426
Rev Neurosci. 2012;23(5-6):747-67
pubmed: 23079510
Front Psychiatry. 2014 Dec 19;5:184
pubmed: 25566103
Schizophr Bull. 2009 May;35(3):509-27
pubmed: 19155345
Psychol Med. 2009 Feb;39(2):179-95
pubmed: 18606047
Arch Gen Psychiatry. 2011 Apr;68(4):361-8
pubmed: 21135315
Emotion. 2005 Mar;5(1):12-22
pubmed: 15755216
Dialogues Clin Neurosci. 2016 Mar;18(1):7-21
pubmed: 27069376
Neuroscience. 2000;96(4):651-6
pubmed: 10727783
Br J Psychiatry Suppl. 2007 Dec;51:s13-8
pubmed: 18055930
J Chem Neuroanat. 2003 Dec;26(4):317-30
pubmed: 14729134
Eur Neurol. 1998;39(2):119-24
pubmed: 9520073
Neuroimage Clin. 2014 Jan 18;4:343-51
pubmed: 24501703
Biol Psychiatry. 2006 May 15;59(10):929-39
pubmed: 16427028
Front Syst Neurosci. 2010 Aug 05;4:
pubmed: 20844603
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9673-8
pubmed: 15976020
Neuroimage. 2011 Feb 1;54(3):2524-33
pubmed: 20951215
Schizophr Bull. 2015 Mar;41 Suppl 2:S408-16
pubmed: 25810055
Curr Opin Psychiatry. 2010 Mar;23(2):91-6
pubmed: 20051858
Brain Connect. 2012;2(3):125-41
pubmed: 22642651
Schizophr Bull. 1991;17(4):555-64
pubmed: 1805349
Neuroimage. 2013 Aug 1;76:439-41
pubmed: 22440651
J Cogn Neurosci. 2012 Feb;24(2):507-20
pubmed: 21861684
Nat Rev Neurosci. 2006 Jun;7(6):464-76
pubmed: 16715055
Neuroimage. 2010 Feb 15;49(4):3110-21
pubmed: 19931396
Cereb Cortex. 2008 Dec;18(12):2735-47
pubmed: 18400794
J Neurosci. 2009 May 13;29(19):6336-47
pubmed: 19439610
Brain Connect. 2012;2(5):246-53
pubmed: 22957904
Brain Struct Funct. 2010 Aug;215(2):73-96
pubmed: 20938681
Trends Cogn Sci. 1998 Oct 1;2(10):379-88
pubmed: 21227253
Schizophr Bull. 2014 Sep;40(5):1095-104
pubmed: 24243441
Front Syst Neurosci. 2013 Dec 06;7:104
pubmed: 24367300
PLoS Comput Biol. 2007 Feb 2;3(2):e17
pubmed: 17274684
J Neurosci. 2013 Mar 13;33(11):4693-709
pubmed: 23486943
Front Hum Neurosci. 2015 Jan 13;8:1047
pubmed: 25628553
Magn Reson Med. 2000 Jan;43(1):45-51
pubmed: 10642730
Schizophr Bull. 2015 Mar;41 Suppl 2:S444-54
pubmed: 25533270
Front Behav Neurosci. 2014 Nov 18;8:382
pubmed: 25477792
Neuron. 2014 Sep 3;83(5):999-1001
pubmed: 25189207
J Neurosci. 2009 Jun 3;29(22):7364-78
pubmed: 19494158
Schizophr Bull. 2009 May;35(3):549-62
pubmed: 19325164
J Neurophysiol. 2009 Jun;101(6):3270-83
pubmed: 19339462
Brain. 2003 Aug;126(Pt 8):1767-81
pubmed: 12805106
Annu Rev Neurosci. 1986;9:357-81
pubmed: 3085570
Neurosci Biobehav Rev. 2013 Mar;37(3):317-27
pubmed: 23313650
Neurosci Biobehav Rev. 2011 Apr;35(5):1110-24
pubmed: 21115039
JAMA Psychiatry. 2015 Jan;72(1):5-13
pubmed: 25372846

Auteurs

Julian Rössler (J)

Collegium Helveticum, University of Zurich; and ETH Zurich, Zurich, Switzerland.

Lui Unterassner (L)

Collegium Helveticum, University of Zurich; and ETH Zurich, Zurich, Switzerland.

Thomas Wyss (T)

Collegium Helveticum, University of Zurich; and ETH Zurich, Zurich, Switzerland.

Helene Haker (H)

Translational Neuromodeling Unit (TNU), Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Zurich, Switzerland.

Peter Brugger (P)

Department of Neurology, University Hospital Zurich, Zurich, Switzerland.

Wulf Rössler (W)

Collegium Helveticum, University of Zurich; and ETH Zurich, Zurich, Switzerland.
Psychiatric University Hospital, Zürich University, Zürich, Switzerland.
Laboratory of Neuroscience (LIM 27), Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil.
Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Berlin, Germany.

Diana Wotruba (D)

Collegium Helveticum, University of Zurich; and ETH Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH